Consorzio Interuniversitario Nazionale per la Bio-Oncologia presents
BREAST CANCER CONTROVERSIES This house believes that …
Chieti, June 27, 2016
Auditorium, G. D’Annunzio University
Directors: Ettore Cianchetti & Clara Natoli
09.45 Registration
10.15 Introduction and Authorities welcome I session
Chairs: Corrado Ficorella, L’Aquila & Clara Natoli, Chieti
10.30 THBT Italian breast cancer screening guidelines should be updated Marzia Muzi, Ortona
10.45 Discussion leader: Doralba Morrone, Florence
11.00 THBT neoadjuvant systemic therapy should be the standard of care for HER2+/triple negative operable breast cancer > 2cm
Valentina Guarneri, Padova
11.15 Discussion leader: Antonio Frassoldati, Ferrara
11.30 THBT selected HER2/++ FISH negative breast cancers should be considered as HER2/+++
Domenico Angelucci, Ortona
11.45 Discussion leader: Patrizia Querzoli, Ferrara
12.00 THBT axillary lymph node dissection should be avoided in patients with 1–2 macro-metastatic axillary lymph nodes
Ettore Cianchetti, Ortona
12.15 Discussion leader: Mario Taffurelli, Bologna
12.30 THBT hypo-fractionated irradiation and partial breast irradiation are recommended after breast conserving surgery
Domenico Genovesi, Chieti
12.45 Discussion leader: Lorenzo Livi, Florence
13.00 THBT chemoprevention and prophylactic surgery should be offered to healthy women carrying BRCA1/2 mutations
Laura Cortesi, Modena
13.15 Discussion leader: Francesco Fanfani, Chieti
13.30 Light lunch
II session
Chairs: Amedeo Pancotti, Teramo & Carlo Garufi, Pescara
14.30 THBT that fertility should be preserved in young women with early breast cancer Gianmario Tiboni, Ortona
14.45 Discussion leader: Lucio Laudadio, Lanciano
15.00 THBT metronomic chemotherapy has an emerging role for early and advanced breast cancer treatment Elisabetta Munzone, Milan
15.15 Discussion leader: Vito Lorusso, Bari
15.30 THBT that neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer women Antonino Grassadonia, Chieti
15.45 Discussion leader: Silvana Leo, Lecce
16.00 Coffee break
16.15 THBT endocrine combination therapies are recommended for RE+ HER2- tumors Katia Cannita, L’Aquila
16.30 Discussion leader: Serena Di Cosimo, Milan
III session –
Chairs: Antonio Nuzzo, Lanciano & Clara Natoli, Chieti
16.45 THBT taxanes and bevacizumab are the standard first line therapy for HER2- metastatic breast cancer Luca Moscetti, Modena
17.00 Discussion leader: Giorgio Mustacchi, Trieste
17.15 THBT metastatic triple positive breast cancer needs different therapeutic strategies than HER2- enriched tumors
Patrizia Vici, Rome
17.30 Discussion leader: Andrea Michelotti, Pisa
17.45 Conclusions
Clara Natoli & Ettore Cianchetti
18.00 Questionario di valutazione dell’apprendimento 18.15 Chiusura dei lavori
